GSK Jemperli - the seventh PD-1/L1 to enter the U.S. marketOctober 07, 2022 - In April, Jemperli became the seventh PD-1/L1 to enter the U.S. market after an approved in previously treated advanced or recurrent mismatch repair-deficient (dMMR) endometrial cancer. It later that year added any dMMR solid tumors—regardless of location—to its label.
This week GSK announced that in a phase 2 trial, GSK’s Jemperli, used in tandem with chemotherapy, shrank tumors as well as Keytruda’s chemo combo in patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer (NSCLC), thus challenging Merck's (MSD) Keytruda dominance in this indication.
https://www.fiercepharma.com/pharma/largest-head-head-trial-pd-1s-lung-cancer-gsk-thinks-jemperli-could-match-mercks-keytruda
[ As Background - In GI cancers, checkpoint inhibitors are only effective in patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors. Oncolytic viruses may improve the susceptibility of microsatellite stable (MSS) tumors to immunotherapy by modifying the tumor microenvironment (TME). Pelareorep (pela) is an intravenously delivered, non-genetically modified, oncolytic reovirus that mediates cancer cell killing by activating innate and adaptive immune responses directed against the tumor as well as direct tumor oncolysis. Accordingly, treatment with pelareorep results in increased T cell infiltration and PD-L1 expression in tumors which primes the TME for responsiveness to checkpoint inhibitors. Pela has demonstrated activity in many cancers including colorectal and pancreatic cancer. The GOBLET study is designed to assess the efficacy of pela plus atezolizumab (atezo) with or without chemotherapy in multiple GI cancers.]
https://www.annalsofoncology.org/article/S0923-7534(22)00829-8/fulltext